Parexel Snags First CRO Contract From Korea Drug Development Fund
This article was originally published in PharmAsia News
Executive Summary
The $467 million fund will match R&D development costs for Korean firms with innovative programs, and will allow the domestic firms to tap into Parexel's global network.